You searched for side effects - Page 41 of 311

Comparing the effectiveness of epirubicin and cyclophosphamide plus taxanes versus carboplatin plus taxanes in early-stage triple‑negative breast cancer.

Posted by Medivizor on Dec 5, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness of epirubicin (Ellence) and cyclophosphamide (Cytoxan) plus paclitaxel (Taxol)/docetaxel (Taxotere) (taxanes) (ECT) versus carboplatin (Paraplatin) plus taxanes (TP) regimens in patients with early-stage triple-negative breast cancer (TNBC). The data showed that both treatment regimens showed...

Can a salt substitute reduce the risk of a stroke and heart events in patients with high blood pressure?

Posted by Medivizor on Dec 5, 2021 in Hypertension | 0 comments

In a nutshell This study investigated if a salt substitute could reduce the risk of stroke and cardiovascular (CV) events in patients with hypertension (high blood pressure). The data showed that the salt substitute reduced the risks of stroke, major CV events, and death from any cause compared to regular salt in patients with hypertension. Some...

Does ND0612 levodopa delivery system improve treatment of Parkinson’s disease?

Posted by Medivizor on Dec 5, 2021 in Parkinson's Disease | 0 comments

In a nutshell This study evaluated the effectiveness and safety of the ND0612 delivery system of levodopa/carbidopa (Sinemet) in patients with Parkinson's disease (PD). The authors showed that the system was well-tolerated and safe and that it reduced the fluctuations of the levodopa plasma levels. Some background Parkinson's...

Evaluating the effectiveness and safety outcomes of durvalumab maintenance after chemoradiotherapy for unresectable stage 3 non-small-cell lung cancer.

Posted by Medivizor on Nov 28, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of durvalumab (Imfinzi) maintenance after chemoradiotherapy (CRT) in real-world patients with unresectable stage 3 non-small-cell lung cancer (NSCLC). The data showed that durvalumab maintenance after CRT was safe and showed good short-term survival outcomes in these...

Evaluating the effectiveness and safety of ixazomib as maintenance therapy after bortezomib-based induction therapy in real-world patients with multiple myeloma.

Posted by Medivizor on Nov 28, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of ixazomib (Ninlaro) as maintenance therapy after bortezomib (Velcade)-based induction therapy in real-world patients with multiple myeloma (MM). The data showed that the outcomes of these patients in the real-world setting were good with manageable side effects. Some background...

Evaluating the effectiveness of T-VEC after failure of immunotherapy in patients with unresectable metastatic melanoma.

Posted by Medivizor on Nov 27, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness of talimogene laherparepvec (Imlygic; T-VEC) after failure of immunotherapy for the treatment of patients with unresectable metastatic melanoma. The data showed that T-VEC after the failure of immunotherapy is safe and effective in these patients. Some background Melanoma is an aggressive type of...

How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?

$How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?$

Posted by Medivizor on Nov 21, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors investigated the safety and effectiveness of epcoritamab (DuoBody-CD3xCD20) for the treatment of patients with relapsed or refractory (r/r) CD20+ B-cell non-Hodgkin lymphoma (B-NHL). The study showed that this medication has promising effectiveness and safety in these patients. Some background B-NHL is a type of...

How effective is iGlarLixi in patients with uncontrolled type 2 diabetes?

Posted by Medivizor on Nov 21, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the effectiveness of insulin glargine 100U/ml (iGlar; Lantus) and lixisenatide (Lixi; Lyxumia) combined (iGlarLixi; Soliqua) compared with each of the two drugs alone in patients with type 2 diabetes (T2D) that was uncontrolled with 2 anti-diabetic oral drugs. The data showed that iGlarLixi...

Daratumumab maintenance therapy after autologous stem-cell transplant in patients with newly diagnosed multiple myeloma.

Posted by Medivizor on Nov 21, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the use of daratumumab (Darzalex) as maintenance therapy following autologous stem-cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (NDMM). The data showed that maintenance therapy with daratumumab resulted in significant improvements in outcomes compared to observation only in patients that...

Evaluating the use of very low dose radiation treatment for painless non-Hodgkin lymphoma

Posted by Medivizor on Nov 14, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study aimed to investigate if very low-dose radiotherapy (VLDRT) was effective in treating patients with indolent (painless) non-Hodgkin lymphoma (NHL). This study concluded that this treatment can be effective in these patients. Some background Radiotherapy (RT) is an important treatment in managing patients...

Evaluating the effectiveness and safety of T-VEC plus surgery for the treatment of patients with resectable advanced stage melanoma.

Posted by Medivizor on Nov 14, 2021 in Melanoma | 0 comments

In a nutshell This study compared the effectiveness and safety of talimogene laherparepvec (Imlygic; T-VEC) plus surgery versus surgery alone for the treatment of patients with resectable advanced stage (III or IV) melanoma. The data showed that T-VEC plus surgery was safe and effective for these patients. Some background Melanoma is an aggressive...

Evaluating the effectiveness and safety of fixed-duration treatment with ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia.

Posted by Medivizor on Nov 14, 2021 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of fixed-duration treatment with ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with previously untreated chronic lymphocytic leukemia (CLL) by using minimal residual disease (MRD) guidance. The data showed that fixed-duration treatment with ibrutinib plus venetoclax was...

Comparing the effectiveness of epirubicin and cyclophosphamide plus taxanes versus carboplatin plus taxanes in early-stage triple‑negative breast cancer.

Can a salt substitute reduce the risk of a stroke and heart events in patients with high blood pressure?

Does ND0612 levodopa delivery system improve treatment of Parkinson’s disease?

Evaluating the effectiveness and safety outcomes of durvalumab maintenance after chemoradiotherapy for unresectable stage 3 non-small-cell lung cancer.

Evaluating the effectiveness and safety of ixazomib as maintenance therapy after bortezomib-based induction therapy in real-world patients with multiple myeloma.

Evaluating the effectiveness of T-VEC after failure of immunotherapy in patients with unresectable metastatic melanoma.

How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?

How effective is iGlarLixi in patients with uncontrolled type 2 diabetes?

Daratumumab maintenance therapy after autologous stem-cell transplant in patients with newly diagnosed multiple myeloma.

Evaluating the use of very low dose radiation treatment for painless non-Hodgkin lymphoma

Evaluating the effectiveness and safety of T-VEC plus surgery for the treatment of patients with resectable advanced stage melanoma.

Evaluating the effectiveness and safety of fixed-duration treatment with ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia.

Categories

Recent Posts

Archives

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email